GlaxoSmithKline

GlaxoSmithKline to invest £500m in Britain

British Government's recent announcement to hack Corporation Tax on income to 10 per cent has encouraged GlaxoSmithKline Plc to increase investment in Britain.

British drug-maker GlaxoSmithKline said it might spend £500 million on building a new factory to make biotech drugs and on the expansion of an existing plant in Ware, Hertfordshire.

The Government's patent box scheme announced by Chancellor Alistair Darling in the Pre-Budget report, will take effect from 2013.

Companies: 
General: 

GlaxoSmithKline to sell Lucozade in China

Drug multinational GlaxoSmithKline said it would sell, Lucozade, the energy drink, in the Chinese supermarkets, a move signifying drug-maker's effort to push itself into the emerging markets of the world.

GlaxoSmithKline has penned a deal with President Trading to distribute it through out China.

Lucozade was first invented by a Newcastle chemist in 1927 to provide ailing children a glucose boost.

Lucozade, which is mainly sold in Britain, Hong Kong and Ireland, generates around 400 million pounds in sales annually.

Companies: 
General: 
Region: 

European Medicines Agency approves GlaxoSmithKline’s swine flu vaccine, Pandemrix

European Medicines Agency has given the green signal to one of UK's swine flu vaccines - the GlaxoSmithKline vaccine, called Pandemrix. The European drugs regulator's recommendation of Pandemrix implies that the vaccine can be used in the European Union within a few weeks, once the licensing formalities are completed.

General: 
Companies: 

Pages

Subscribe to RSS - GlaxoSmithKline